Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study
Abstract To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated wit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-81195-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850135777628913664 |
|---|---|
| author | Toshihiko Matsumoto Sien Cho Akio Nakasya Hiroki Nagai Hironaga Satake Hisateru Yasui |
| author_facet | Toshihiko Matsumoto Sien Cho Akio Nakasya Hiroki Nagai Hironaga Satake Hisateru Yasui |
| author_sort | Toshihiko Matsumoto |
| collection | DOAJ |
| description | Abstract To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated with anamorelin. We evaluated the efficacy of treatment by measuring the improvements in appetite and body weight (BW) gain. Between June 2021 and October 2022, 43 cancer patients with cachexia—23 with gastric cancer and 20 with colorectal cancer—were treated with anamorelin. Median observation period was 7.3 months. The participants were 25 males with median age of 71 years and median BMI of 19.7. The ECOG PS distribution was 4, 33, 6 for grades 0, 1, and 2, respectively. Seven patients received supportive care only, while 36 received anamorelin with chemotherapy. Thirty-four had received chemotherapy previously (≤ 2 regimens) and nine had received ≥ 3 regimens. Median anamorelin treatment duration was 2.8 months; overall survival was 7.3 months. After 3 weeks, 24 experienced appetite improvement and 21 gained weight; after 12 weeks, 20 experienced appetite improvement and 15 gained weight. Multivariate analysis showed that anamorelin treatment before second-line chemotherapy and colorectal cancer correlated with appetite improvement and weight gain at 3 weeks. In the univariate analysis, anamorelin treatment before second-line chemotherapy correlated with weight gain at 12 weeks and with improved overall survival in patients with weight gain at 12 weeks. Early anamorelin treatment contributes to appetite improvement and BW gain in colorectal and gastric cancers with cachexia. |
| format | Article |
| id | doaj-art-0d386e630c9c45d795e213ed4e210345 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0d386e630c9c45d795e213ed4e2103452025-08-20T02:31:18ZengNature PortfolioScientific Reports2045-23222024-12-011411910.1038/s41598-024-81195-3Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational studyToshihiko Matsumoto0Sien Cho1Akio Nakasya2Hiroki Nagai3Hironaga Satake4Hisateru Yasui5Department of Medical Oncology, Ichinoimiya Nishi HospitalDepartment of Medical Oncology, Kobe City Medical Center General HospitalDepartment of Medical Oncology, Kobe City Medical Center General HospitalDepartment of Medical Oncology, Kobe City Medical Center General HospitalDepartment of Medical Oncology, Kobe City Medical Center General HospitalDepartment of Medical Oncology, Kobe City Medical Center General HospitalAbstract To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated with anamorelin. We evaluated the efficacy of treatment by measuring the improvements in appetite and body weight (BW) gain. Between June 2021 and October 2022, 43 cancer patients with cachexia—23 with gastric cancer and 20 with colorectal cancer—were treated with anamorelin. Median observation period was 7.3 months. The participants were 25 males with median age of 71 years and median BMI of 19.7. The ECOG PS distribution was 4, 33, 6 for grades 0, 1, and 2, respectively. Seven patients received supportive care only, while 36 received anamorelin with chemotherapy. Thirty-four had received chemotherapy previously (≤ 2 regimens) and nine had received ≥ 3 regimens. Median anamorelin treatment duration was 2.8 months; overall survival was 7.3 months. After 3 weeks, 24 experienced appetite improvement and 21 gained weight; after 12 weeks, 20 experienced appetite improvement and 15 gained weight. Multivariate analysis showed that anamorelin treatment before second-line chemotherapy and colorectal cancer correlated with appetite improvement and weight gain at 3 weeks. In the univariate analysis, anamorelin treatment before second-line chemotherapy correlated with weight gain at 12 weeks and with improved overall survival in patients with weight gain at 12 weeks. Early anamorelin treatment contributes to appetite improvement and BW gain in colorectal and gastric cancers with cachexia.https://doi.org/10.1038/s41598-024-81195-3AnamorelinRetrospective studyCachexiaCancer |
| spellingShingle | Toshihiko Matsumoto Sien Cho Akio Nakasya Hiroki Nagai Hironaga Satake Hisateru Yasui Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study Scientific Reports Anamorelin Retrospective study Cachexia Cancer |
| title | Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study |
| title_full | Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study |
| title_fullStr | Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study |
| title_full_unstemmed | Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study |
| title_short | Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study |
| title_sort | early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients an observational study |
| topic | Anamorelin Retrospective study Cachexia Cancer |
| url | https://doi.org/10.1038/s41598-024-81195-3 |
| work_keys_str_mv | AT toshihikomatsumoto earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy AT siencho earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy AT akionakasya earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy AT hirokinagai earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy AT hironagasatake earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy AT hisateruyasui earlyadministrationofanamorelinimprovescancercachexiaingastrointestinalcancerpatientsanobservationalstudy |